FDA approved Skinvive by Juvéderm to reduce neck lines and improve neck appearance in adults over the age of 21.

The approval marks the first and only hyaluronic acid injectable specifically indicated for neck wrinkles and expands the existing Skinvive franchise, which had previously been indicated for cheek skin quality, into a new anatomical area and addresses a growing aesthetic concern driven in part by the prevalence of "tech-neck.”¹

What is Skinvive by Juvéderm and how does it work?

Skinvive by Juvéderm is a hyaluronic acid injectable designed not to add volume or fill wrinkles in the conventional sense, but to help the skin retain its natural moisture, softness, and smoothness. Applied using an ultrafine needle or cannula, the treatment is minimally invasive with little to no downtime and contains a small amount of lidocaine to support patient comfort during administration.¹ Results last six months with optimal treatment, which may include an optional touch-up one month after the initial session.

The mechanism distinguishes Skinvive from traditional filler products. Rather than structurally lifting or filling a crease, the hyaluronic acid formulation works at the level of skin hydration and texture, a positioning that Allergan says addresses an unmet need in the lower face and neck category where existing injectables have not been specifically studied or approved for this indication.¹

What did the clinical data show?

FDA's approval was based on a randomized, multicenter, evaluator-blinded, controlled pivotal study. At one month following treatment, 74.8% of participants treated in the neck with Skinvive by Juvéderm showed a clinically significant improvement of at least one point on the validated five-grade photonumeric Allergan Transverse Neck Lines Scale.² The majority of participants maintained that level of improvement at six months.² Among those who demonstrated improvement from baseline in overall score, the proportion staying improved remained at 78% or higher at all timepoints throughout the study.

"The approval of Skinvive by Juvéderm for horizontal neck wrinkles reflects Allergan Aesthetics' commitment to developing science-driven innovations that address meaningful unmet aesthetic needs," said Darin Messina, PhD, senior vice president, aesthetics R&D at AbbVie. "This approval expands our portfolio of lower face and neck treatment options and gives patients and aesthetic providers a first-of-its-kind treatment option for improving neck skin quality and reducing the appearance of neck lines."1

What is the safety profile?

Adverse events reported in the clinical study included redness, bruising, tenderness, swelling, lumps and bumps, firmness, pain, discoloration, and itching at the injection sites.² Most events were mild, did not require treatment, and resolved within two weeks. Severe adverse events were reported in fewer than 5% of participants, and adverse event rates were similar or lower following touch-up and repeat treatments.¹

As a condition of approval, FDA has required Allergan Aesthetics to provide a mandatory training program for all providers before they can purchase or administer the product for this indication.¹

Sources

1. Allergan Aesthetics Receives U.S. FDA Approval for Skinvive by Juvéderm for the Improvement of Neck Appearance AbbVie June 16, 2026 https://www.prnewswire.com/news-releases/allergan-aesthetics-receives-us-fda-approval-for-skinvive-by-juvederm-for-the-improvement-of-neck-appearance-302800848.html
2. A Study to Evaluate the Safety and Effectiveness of Juvéderm Products in Adult Participants for the Change of Their Overall Facial Appearance National Library of Medicine February 23, 2026 https://clinicaltrials.gov/study/NCT07186595